Biosimilar Market Access and Commercialization Strategies Summit – Biosimilar Market Access and Commercialization Strategies Summit

The FDA’s approval of the first wave of biosimilars cleared the way for manufacturers to make lower-cost versions of expensive biologic drugs, saving patients money and improving access to important medications. There is a significant market opportunity ahead for biosimilar drugmakers; by 2020, leading biologic medicines worth more than $80 billion global annual sales will lose their patent protections, and biosimilars is the largest area for potential growth in the biotech sector. But with great rewards, there are also great risks that must be considered. In contrast to Europe, this is still an uncharted territory for the US market, and barriers to market access are not as low as they seem to be. From FDA approval to pricing and marketing strategies, there are risks and financial uncertainties. Therefore, the industry needs to know how to best address those challenges and optimize the biosimilar launch process.

Whether you are exploring your chances of tapping into the competitive biosimilars marketplace or are an expert in the field, the Biosimilar Market Access and Commercialization Strategies Summit will provide detailed presentations, intensive case studies and collaborative panel discussions relevant to your interests. Our talented faculty will address everything from navigating evolving regulations, analyzing optimal pricing models, accelerating market access strategies, and executing strategic decisions to mitigate risk and build for commercial success. In addition, designated lunches and networking breaks will enhance the exchange of knowledge and foster future business partnerships.

Featured Speakers Include:

Top Five Reasons to Attend

  1. Explore factors to consider before developing biosimilars — improve your chances on the road to approval and commercial success
  2. Hear best practices and case studies for a successful biosimilar product strategy from its conception to execution
  3. Stay up to date with FDA guidances and other regulatory guidelines and join the debate on nonproprietary naming of biological and biosimilar products
  4. Navigate biosimilar policies, regulations and compliance issues under the new administration
  5. Network with leaders in the industry and get tips on how to manage payer and provider considerations for market entry, engage with patients, and stay competitive

Who Should Attend

This conference is designed for biotech professionals responsible for:

  • Biosimilars
  • Biologics/Biotechnology/Biogenerics
  • Biopharmaceuticals/Biotherapeutics
  • Market Access Commercialization
  • Marketing and Sales
  • Strategic/Corporate Planning
  • Pricing and Reimbursement
  • HEOR and Outcomes Research
  • Legal Affairs
  • Intellectual Property
  • Medical Affairs
  • Manufacturing/Bioprocesses
  • Clinical Affairs/Operations/Development
  • Regulatory Affairs
  • Medical Science Liaisons
  • R&D
  • Quality Control/Assurance

This event is also of interest to:

  • CROs/CMOs/CMDOs
  • Law Firms
  • API Manufacturers
  • Distributors
  • Consulting Companies
  • Market Access Providers
  • Licensing Services
  • Distribution and Logistics Services
  • Packaging and Labeling Companies
  • Preclinical/Nonclinical/Analytical Development Research Organizations
Startdate: 2017-09-18
End Date 2017-09-19

Description: Biosimilar Market Access and Commercialization Strategies Summit is the leading event for biotechnology leaders active in biosimilars drug availability
Performer: ExL Events
Address : 425 Summer Street Biosimilar Market Access and Commercialization Strategies Summit
Boston
MA
USA